Jimtash, the backlog on RCE examinations is HUGE and will take years. I looked at another patent I know that went back for re-examination and it has been almost 2 years and nothing yet.



Request for Continued Examination (RCE)


Here is an article about the backlog.

"It seems rather clear that the USPTO has traded an unacceptably high unexamined patent application backlog for a still unacceptably high but better unexamined patent application backlog PLUS a ridiculous RCE backlog"



"“I am prosecuting an application where an RCE was filed in early 2011. After almost two years, it is about 20th in queue on the examiner’s special new docket. If the examiner follows USPTO policy and examines one case from that docket every other bi-week, it will be late 2014 before this case receives an Office Action. The news is worse for other applications assigned to this examiner, because his current special new docket includes about 50 cases. If the examiner follows USPTO policy and examines 13 cases from that docket every year, the most recent RCEs will wait four years for an Office Action.”



http://www.ipwatchdog.com/2013/02/14/the-rce-backlog-a-critical-patent-office-problem/id=35431/

http://thepinksheetdaily.elsevierbi.com/deals/200610159

http://thepinksheetdaily.elsevierbi.com/deals/200610159

http://www.radient-pharma.com/pdf/press_releases/2010/062410%20CIT%20Phase%20II%20Clinical%20Trials.pdf

http://www.pipelinereview.com/index.php/2010120738904/Strategy/Radient-Pharmaceuticals-Announces-Formation-of-New-Subsidiary-NuVax-Therapeutics-Inc.html


Of course, the third link above was all another lie by MacLellan.

b_b, Wolfie over on the Yahoo board made a post about William Gartner, the founder of GCDX, selling one of his homes in the Phoenix area in order to pay for the patent costs for Radient.

That is absolutely absurd and just more of the drivel Wolfie posts.

Cashking, I could care less if you gamble whatever you want on a worthless penny stock but I do object to you posting that a worthless stock is valuable just because you claim the test works great and have some sort of "inside information" you will not disclose.

The test does not work well and that is it's problem.

In its best year, Radient never had more than $300,000 in product sales of Onko Sure a year so a company who owes over $18 million with interest of $3.2 million per year on that debt, it is death spiral from which there is no recovery.

What is even worse, the reported sales in 2011 were less than the sales in 2010 and the sales in quarter 4 of 2011 were down the most.

Cashking, you need to truly understand the facts about Onko Sure and not some of the hype put out by Radient. Surely you do understand the reason why the Radient class action suit is in progress. MacLellan was lying about that hype.


First of all, it does not detect cancer in stage one with any reliablity at all. You would get better results from a flip of a coin. What Radient was hyping was Onko Sure detecting cancer earlier than CEA but CEA is totally worthless to detect cancer in stage I and II. So how much better do you have to be to be better than something that is worthless?

Do you ever wonder why the medical community has not jumped all over this test if it is as good as you claim? The test doesn't perform well. That is why the sales in the USA were nil. Genway has now dropped the test from their website. Onko Sure has way too many false positives. I suggest you read the FDA submission for the approval to monitor colorectal cancer. A study is mentioned where Radient eliminated from the control group people who had any one of many conditions that would cause an elevated level of fibrin. THAT'S CHEATING.

Now, I will agree that you can monitor colorectal cancer with this test but in reality, it does not perform as well as CEA in stages III and later and it performs poorly in stage I and II.

These are facts CashKing and you need to face reality. Stop looking at your cloudy crystal ball and begin reading some factual material.

Cashking, the lenders continue to sell shares. They just don't have the TA issue shares on a daily basis and pay $35 for each day per lender. They wait and convert a bunch of shares at one time and sell short based on shares to be converted.

If there were any good news to come from this company, MacLellan would have put out another 8K. As it is, they cannot even afford the expense of a press release. That is why the past events have been released in the form of an 8K.

Someone is certainly unloading shares at $.0001 today and you can be assured it is the lenders. The O/S share count doesn't go up every day because the lenders no longer have the TA issue shares on a daily basis. Each transaction with the TA costs $35 and that equals the amount they would get from selling 350,000 shares. Why would 7 lenders each waste the money each day in converting shares when their broker allows them 45 days to cover the short sale.

When the short report comes out every two weeks, unresolved trades are not included.




$0.0001

1,000,000

OTO

14:58:41




$0.0001

1,000,000

OTO

14:58:21




$0.0001

1,000,000

OTO

14:58:09




$0.0001

1,000,000

OTO

14:57:54




$0.0001

1,000,000

OTO

14:57:42




$0.0001

1,000,000

OTO

14:57:25




$0.0001

1,000,000

OTO

14:57:03






$0.0001

400

OTO

12:22:33




$0.0001

999,999

OTO

11:52:05





$0.0001

100

OTO

11:11:53






$0.0001

5,056

OTO

10:47:28




$0.0001

539

OTO

10:38:32




$0.0001

200

OTO

10:32:36




$0.0001

1,239

OTO

10:25:34




$0.0001

200

OTO

10:25:08




$0.0001

400

OTO

09:30:04

Cashking, there are NO share held in reserve by Radient. The shares outstanding right now seem to be around 3.7 billion as stated by the TA in emails. Any shares if still held by any of those you mentioned in a previous post would be included in that 3.7 billion.

The lenders can still sell the other 1.3 billion up to the maximum of the 5 billion authorized limit.

Soloman, the conversations between the CEO and the lenders have only been how to convert their notes and sell shares. The last agreement totally removed previous restrictions on the number of shares they are allowed sell.

They can now sell an unlimited number of shares up to the authorized share limit. Radient did not even complete their obligations as set forth in the latest agreement.

Cashking, that is certainly an OLD report. The owners of Jade were given stock in AMDL to complete the purchase of Jade about 6 years ago. That is one of the reasons the owners of Jade felt they got shafted and that AMDL had stolen their company.

It would be insane to base any decisions on that report.

Jimtash stated: "The patent examiner isn't going over the entire patent again. Just parts of it that led to it being rejected."

REALLY? Just the parts that led to the rejections???

Jim, EVERY CLAIM WAS REJECTED.

This is not going to be resolved anytime soon and besides, no one but a few on this board are waiting with bated breath for a decision on this patent.

This isn't going to stop anyone from selling a test based on the first expired patent and soon to expire second patent. You are just grasping at straws.

Will Radient ever declare bankruptcy?

I don't think so. There is no advantage for Radient to declare. It just costs money which Radient doesn't have. A chapter 11? No way. That requires refinancing and a debtor in possession. No one is going to put any real money at risk for a company with a less than marginal product.

MacLellan will just let the lenders take any assets they can but even the lenders now know that taking any assets may not even be worthwhile. IMO, this stock is just going to blow in the wind until the lenders reach the authorized share limit. At that point, the volume is just going to dry up.

Who profits from closing the stock at .0001?

It's the LENDERS. Read the SEC flings to verify how the loans are converted.

The lender convert their notes at 80% of the lowest 3 day average in the past 20 days.

The lenders first have their broker sell shares to later be covered by shares sent to the broker from the transfer agent. The transfer agent charges $35 per transaction. They sell the shares at whatever price the market allows and make more money if the conversion price is lower.

If the stock closes at .0002 for 3 business days, then the lenders would get each share for $.00016.

If the stock closes at .0001 for 3 business days, then the lenders would get each share for $.00008.

Now, do you understand why they close the stock at .0001?

“Conversion Price” means, as of any Conversion Date (as defined below) or other applicable date of determination, the lowest of (i) the Fixed Conversion Price (as defined below), (ii) the price which is equal to the product of (1) 80% multiplied by (2) the quotient of (A) the sum of each of the three (3) lowest daily Weighted Average Prices (as defined below) of the Common Stock during the twenty (20) consecutive Trading Day (as defined below) period immediately preceding the applicable Conversion Date or other applicable date of determination (as applicable) divided by (B) three (3) (as adjusted for any stock split, stock dividend, stock combination or other similar transaction during any such twenty (20) Trading Day period) and (iii) the price which is equal to 80% of the Closing Bid Price of the Common Stock on the Trading Day immediately preceding the applicable Conversion Date or other applicable date of determination (as applicable) (as adjusted for any stock split, stock dividend, stock combination or other similar transaction occurring on the applicable Conversion Date or other applicable date of determination (as applicable)).


Below are the lendeers.


Iroquois Master Fund Ltd.
Cranshire Capital, L.P.
Freestone Advantage Partners, LP
Bristol Investment Fund, Ltd.
Kingsbrook Opportunities Master Fund LP
Alpha Capital Anstalt
Whalehaven Capital Fund, Ltd.

Sport asked: "Gold why is the bid so high?
"

You really don't understand why the bid at .0001 is so high? Really?

Well, most sales have now been at .0002 so anyone thinking they can buy at .0001 and sell at .0002, would double their money. That's rather easy isn't it?

This is not some fabulous stock so I would say that most interest in the stock is for trading purposes and not some long term investment so sure, go for and bid some more at .0001. The lenders do not have that much more to sell before they max out the authorized shares so the odds of them going back to selling at .0001 is not likely unless the sales at .0002 absolutely dry up.

Jimtash, I have looks at the unresolved trade volume on low trade dayss and you can see that the sales at .0002 equate to that volume. The lenders only sell at .0001 in small volume to lower the average closing price and increse their sales margin on the rest of their salse.

Jimtash, It took MONTHS for the lenders to finally move up the ask from .0001 to .0002. Why?

Well, there are 5 note holders involved in the 2011 financing. They are all independent. In addition, there are Alpha and Whale from the 2010 financing so you have up to 7 sellers all getting their shares at a 58% discount to market so which seller is going to move up to the .0003 ask and let one of the lenders continue to sell at .0002 and take all the sales.

Do you finally understand? They all use computer trading programs.

Wolfie, that IS how it works. For you to say otherwise is clearly saying you have not read the SEC filings. You can certainly be assured that I have read EVERY Radient filing.

Well Wolfie, you are wrong again. The lenders are NOT holding shares. They sell Radient shares and then convert at 58% of the 5 day average closing. Who do you think is closing the stock at .0001 most days? That keeps the average down and lets them make more money selling at .0002. read the SEC filings.

Jimtash, the lenders are NOT "holding on to shares". That's not they way their note conversion works.

If you would just read the SEC filings, you would understand that the lenders have their broker sell shares with a guarantee that Radient's transfer agent will deliver the shares to cover the sale within 45 days.

That's the way it works. Radient will no longer pay the transfer fees so the lenders now each have to pay transfer fees to get the shares delivered to their broker.

Jimtash, if the lenders were not dumping, how do you explain the O/S sharecount of 3.7 billion and growing?

Radient certainly cannot be selling shares. They have no current registration filing and CANNOT get one approved because of past due filings.

Why drop all the email services on the websites and go to yahoo mail accounts? The only reason I would have is to reduce the hosting cost of the website. Email service does not cost much so Moro is going absolutely bare bones until the entire operation is closed down.

Mike, you might make some small change when the lenders finally max out the 5 billion authorized shares but when the volume dries up, most will attempt to salvage something so it is all a gamble but for sure, don't ever think Radient will rise from the ashes, It just won't happen and don't base any investment on wishful dreams like I hear on this board.

Mike, I have nothing against anyone who wants to gamble some money on a sub penny stock but what I do find annoying is for someone to make false claims about the worth of a stock. I am nearly 70, retired and enjoy reading.

I don't like to see someone enticed to buy this type of stock when they really can't afford to lose the money. I will continue to post factual information about this stock as long as anyone continues to post false information.

I do understand that a lot of people don't read SEC filings and that is sad. The only winners here will be the lenders who continue to sell shares. The rest will lose everything, it is only a matter of time.

I also post on IHUB about another stock. For more than 4 years, I have been stating that BOCX is a worthless stock. At the time I began posting that, the stock was 45 cents. It went to .0002, reverse split by 150 and is now just over a penny. They have closed their lab, ceased contact via phone and the lenders are seizing assets. I know that for a fact. The stock will probably continue to blow in the wind just like this one but it is indeed worthless also.

RunCoach, as you know, until a few days ago, Jimtash thought patents could be renewed by paying a fee. He had no idea that patents actually expire after the allotted time period.

For him to now be considered by some to be the Radient patent "expert" is foolish at best.

Jimtash stated: "If Dr-70/Onko Sure is all a flop like some say, then why even rehash it?"

I continue the discussion because youself and others seem to mistakenly believe that DR-70 and some 4 year old patent application is going to be the salvation of Radient.

You are simply incorrect. DR-70 failed BADLY in a marketing attempt back in 2001 and is failing now. Back in 2008, AMDL, now Radient, mentioned in a conference call they were attempting to sell off the DR-70 test. That effort to sell off the division obviously faile for lack of any buyer and then Jade blew up in their face.

MacLellan had nothing left after the Jade fiasco but DR-70 so what does he do? Fold the company up? No, he decides to hype DR-70, lie about the Mayo clinic, change the name of the company and the name of DR-70 to Onko Sure and press on. It was all a failure from that point on.

Do so research into the history of AMDL and you will understand the big picture.

BTW, it is a fact that the TM part of the Chinese test stands for Tumor Marker just as Cashking stated.

Also, the stock in Jade held by Radient is NON VOTING preferred shares. They are worthless. Radient has no say at all in anything Jade does.

Cashking stated: "the company that RXPC owns in china will be matifacturing the test kits"

First of all, the only company radient ever owned was Jade. In an agreement with Jade, they exchanged their control of that company for NON VOTING preferred shares which are worthless to get Jade to release some money. Radient has no control over Jade and has written off the investment.


The Chinese BioTech currently manufacturing the DR-70TM test is NOT Jade and there is no connection with them and Radient.

Jimtash stated: "Looks like GDx is the exclusive partner"

NOPE, More false information posted by you. That agreemnt was CANCELLED. There is no connection, agreement or anything else between GCDX and Radient. It was all CANCELLED.

Jimtash, do you think this patent application is the only one the examiner is looking at? She has lots of them to examine and may not get back around to this one for MONTHS and you still have the interference with Junda to worry about.

All that was resolved in the newest resubmittal was correcting the date of the Genway material. Nothing much more.

RunCoach, in the last 8K, it stated that the agreement was cancelled.

"As of October 1, 2012, GCDx has not made the required upfront payment of $280,000. Therefore the proposed GCDx licensing agreement was cancelled. We will consider re-engaging GCDx in a new licensing agreement at such time as GCDx is able to make the required up-front payment."

Somehow in MacLellan's mind, this became a "proposed" agreement when in reality, an agreement was made and GCDX did not follow through with payment within the time frame allowed.

There was no date set for transfer of all the material on DR-70 and I suspect that was completed over the 4 month period then GCDX bailed.

Jimtash stated: "We shall see but why rehash a 4 year old patent application?"

Don't you understand? That 4 year old patent application is the one you are supposedly waiting with bated breath for approval.

Jimtash stated: "Can it be because Genway also made claims to DR-70 but finally acknowledged that Radiant was the first to file the patent application? And now Radient is free and clear to actually pursue the patent and according to the patent office, the prior Genway arguments aren't standing in the way of anything?"

What on Earth are you talking about? GenWay was not attempting to do ANYTHING with the patent. GenWay just signed a 3 year license to sell Onko Sure and published information and procedures for doctors to run and analyze the test. There was some confusion about the date GenWay published the data and Dr. Howard countered that basis of rejecting the patent based on prior art. There are still other basis for rejecting the patent, Namely, Junda.

GenWay has now removed Onko Sure from their website since the license agreement has expired and they appear to no longer be attempting to sell the test.

Another USA distributor down the tubes.

Wolfie, now you are posting more false information.

You stated: "I don't think there ever was an "agreement" completed based on the several filings."

That is absolutely false. MacLellan stated the followiing.

"On July 13, 2012, we entered into a license agreement with Global Cancer Diagnostics, Inc"


http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/v318772_ex10-1.htm

The above agreement transferred every piece of material Radient had preoduced, memos, studies, methods and everything regarding the manufacturing of DR-70.

Once the transfer was complete, why would GCDX want to continue a license agreement. They had everything they needed to produce a generic test based upon an expired patent. Now, they can manufacture and sell LC Sentinel or whatever they want to call it and what is Radient going to do? Sue? They have no money for that.

Jimtash stated: "The examiner noted the pending 112, 1st set forth in the Final Rejection mailed August 17, 2012 would likely be withdrawn"

READ THE FINAL REJECTION. The section 112 was only One of several reasons for rejection. This does not mean the other objections are going to be lifted also.

Again, READ the claims and rejection.

This patent application is meaningless anyway. Other manufacturers can just say they are making and selling a generic test on the basis of the expired first patent. Radient has no means of conducting a patent fight. Besides, the entire sales of Onko Sure for one year would not even pay for a few hours worth of lawyer fees.

Patent application.

Jimtash stated: "And as has been mentioned, Onko Sure/DR-70 is being used in combination with other tests to get results"

Jim, read the patent. The claims mention NOTHING about monitoring or the use of DR-70 in combination with anything.

This patent is mostly a retatement of the other two older patents and I doubt it will be granted.

Cashking, no one is going to merge with Radient and assume over $18 million in debt. If there was anyone interested in buying the shell, a bankruptcy would eliminate the current shareholders and note holders so as investors, you lose either way.

Sport, sales of penny stocks are hard to understand. One other company I follow, BOCX, has recently closed their lab, wont answer their phone any more, Left a taped message giving a yahoo address to contact them, they have defaulted on a loan and the lender is in fact taking the assets.

The stock price is still selling for up to 3 cents. All investors would have to do is call that number and listen to the tape to see the company is going out of business. I don't think investors do much dd at all when buying penny stocks. Radient is an excellent example also. Anyone who actually read the filings wouldn't touch this stock with a 10 foot pole.

Jimtash, I looked at the links you provided and it looks like Radient has paid the fees necesasary to continue the patent effort. They are not paying many bills unless their sales on Onko Sure have greatly increased. They only had processed antibody for 200 kits so at $400 per kit, that would be $80,000 in revenue from sales since June of 2012 without paying for a scientist to work full time in processing antibody.

Too bad that MacLellan is not saying what is going on but if he told the truth, it might help pay off the lenders or if the truth was negative, kill the stock price and tick off the lenders even more.

What I had been looking at was a statement that funds were not submitted and payment was from the account.

Your link clearly states that payments have been made. thanks.

ALERT*** 3/8/13 BioCurex shuts down lab. Lenders in the process of taking assets. ***ALERT

Jimtash, the patent application has no changes to the claims. All that Dr. Small-Howared did was refute the statement by the examiner that the information from GenWay was prior art.

Also, the fees for the patent were applied from a pre paid account and had nothing to do with GCDX. That is a dream by the wolfman who posts on Yahoo.